November 15, 2010

Pressure BioSciences, Inc. to Discuss Third Quarter 2010 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) today announced that the Company will host a teleconference to discuss its Q3 2010 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Tuesday, November 16, 2010
Time: 4:30 p.m. Eastern Standard Time (EST)

To attend this teleconference via web-cast, please visit the Company's website: www.pressurebiosciences.com

To attend this teleconference via telephone:
Dial-in number: (866) 834-4534

For those unable to participate in the live teleconference, a replay will be accessible through the Company's website approximately one hour after the call ends through December 26, 2010.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development and sale of instruments and consumables based on a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical and enzymatic reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

CONTACT: Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Joseph Damasio, Jr., Controller
508-230-1828

Source: Pressure BioSciences, Inc.